Rescue of Behavioral and neurodegenerative phenotypes in symptomatic tau KO mice: Therapeutic implications for neurodegenerative diseases

peng lei,scott ayton,david i finkelstein,ashley i bush

DOI: https://doi.org/10.1016/j.jalz.2013.08.017

2013-01-01

Alzheimer s & Dementia

Abstract:Recently, we and others reported that aged-tau knockout mice exhibit behavioural deficits, arguing for a role of functional tau protein in brain health. We also showed that these mice exhibit iron-dependent neurodegeneration and clioquinol (CQ), a drug that binds to iron, prevented the development of symptoms in tau KO mice. However, prospective treatments for neurodegenerative disorders will need to confer benefit to symptomatic patients. Here, CQ was given to symptomatic 12-months old tau KO mice to test whether this treatment was effective. Tau knockout mice (tau KO) and background C57BL6/SV129 control mice (WT), at 12 months of age, were treated with CQ chow (30mg/kg body weight /day) for 5.5 months. We monitored the mice by pole test and rotarod every three weeks during treatment period, and terminated this study when the mice were 17-months of age. Y maze tests were performed before the mice being euthanized for biochemical studies. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by HPLC. Before treatment commenced, tau KO mice exhibited cognitive loss (y-maze) and parkinsonism (rotarod, pole test), as previously reported. Over the course of the study, CQ treatment reversed the motor and cognitive impairment as evidenced by improvement in the Pole test (P<0.001) and Rotarod test (P=0.008) and y-maze (P=0.038). Restoration of behavioral disability reflected preservation of neuroanatomical features including enlargement of cortical thickness (P=0.026) and striatal enlargement (P=0.001) and reduction of the lateral ventricular area (P<0.001) at the conclusion of the study. These benefits conferred by CQ treatment could be attributed to reduction in iron load in the brain since treatment with CQ for 5.5 months had decreased iron in the brain (P=0.003 for hippocampus, and P=0.007 for SN) but not liver. Copper and zinc levels were unaffected. Here we report that iron chelation by CQ rescued several neurodegenerative phenotypes of aged tau KO mice, further supporting our hypothesis that tau plays a crucial role in age-related diseases. Importantly, these benefits were conferred to mice that began treatment after symptom manifestation, highlighting the potential for iron chelation approaches as disease modifying therapeutics for neurodegenerative diseases.